RedHill's 2nd try COVID pill staves off hospitalization in phase 2

RedHill Biopharma's daily oral antiviral, upamostat, staved off hospitalization in all 41 patients with symptomatic COVID-19 in the phase 2 portion of a small phase 2/3 study.

The patients, who were symptomatic and had not been hospitalized before treatment, were able to avoid a trip to the hospital. In the placebo arm of the phase 2, three of 20 patients required hospitalization.